These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20831770)

  • 1. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
    Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
    Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Lee WS; Suh C; Kim HJ
    Int J Hematol; 2010 Oct; 92(3):510-7. PubMed ID: 20838958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics, efficacy, and prognosis analysis of newly diagnosed marginal zone lymphoma.
    Wang H; Zhang Y; Li Z; Bai O
    Front Immunol; 2024; 15():1466859. PubMed ID: 39376572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
    Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Lee SI; Kang HJ; Choi CW; Park J; Song MK; Kim HJ; Kwon JH; Kwak JY; Bae SH; Park BB; Do YR; Lee HS; Jeong SH; Suh C; Kim HJ
    Int J Hematol; 2012 Nov; 96(5):631-7. PubMed ID: 23065471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of Upfront Therapy for Marginal Zone Lymphoma.
    Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
    Oh SY; Kim WS; Lee DH; Kim SJ; Kim SH; Ryoo BY; Kang HJ; Choi YJ; Chung JS; Kim HJ; Suh C
    Invest New Drugs; 2010 Apr; 28(2):171-7. PubMed ID: 19421710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
    Oh SY; Kim WS; Kim SJ; Kim JS; Kim SH; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Kim JG; Yang DH; Kang HJ; Choi CW; Park J; Choi YJ; Kim HJ; Kwon JH; Suh C; Kim HJ
    Am J Hematol; 2009 Dec; 84(12):826-9. PubMed ID: 19890833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
    Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
    Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
    Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
    Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
    Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
    Kang HJ; Kim WS; Kim SJ; Lee JJ; Yang DH; Kim JS; Lee SR; Lee GW; Kim HJ; Kim HY; Oh SY; Kim HC; Eom HS; Chung J; Park J; Suh C; Ryoo BY
    Ann Hematol; 2012 Apr; 91(4):543-51. PubMed ID: 21922208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
    Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
    Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea.
    Kim SJ; Yoon SY; Chua S; Byun H; Kim J; Ng J
    Ann Hematol; 2024 Sep; 103(9):3615-3625. PubMed ID: 39103723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
    Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
    Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.